The aim of the study was to determine the roles of microRNA (miR)-146a onmyocardial infarction(MI)-induced heart failure and cardiac remodeling. Experiments were carried out in Sprague-Dawley rats treated with ligation of left coronary artery to induce heart failure, and in primary neonatal rat cardiac fibroblasts (CFs) and cardiomyocytes treated with angiotensin (Ang) II. Four weeks after MI, rats were injected with miR-146a antagomiR or agomiR via tail vein. Continue reading →

AIM: The aim of the study was to determine the frequency of bacterial or fungal mouth infections inmyocardial infarctionpatients treated with primary coronary intervention. A total of 128 patients took part in the study (68 patients in the study group and 60 in the control group). The medical histories of the patients were taken, and the following tests were performed: a physical examination and an oral hygiene assessment. Continue reading →

PHILADELPHIA The investigational drug apabetalone (Resverlogix) did not reduce the risk for major adverse cardiovascular events (MACE) in BETonMACE, a phase3 trial of patients who had recent acute coronary syndrome (ACS), type2 diabetes, and low HDL cholesterol. But this might be because the trial of this novel agent which acts at the epigenetic level, turning genes on and off was underpowered, both the lead author and an outside expert suggest. Apabetalone inhibits bromodomain and extra-terminal (BET) proteins, which are epigenetic transcription modulators of inflammation, thrombogenesis, and lipoprotein lipid metabolism. Continue reading →

LOS ANGELES--(BUSINESS WIRE)--OTITOPIC A clinical-stage dry powder inhalation of aspirin pharmaceutical company pioneering the development of antithrombotic treatments for use at the time of suspected acute myocardial infarction (MI), today announced the successful conclusion based on PD results of a clinical trial for its lead drug: Dry Powder Inhalation of Aspirin (ASPRIHALE). ASPRIHALE is considered to be safe and well tolerable Continue reading →

A recent review and meta-analysis focus on the role of legumes in heart health. Taking data from multiple studies and earlier analyses, the authors conclude that legumes might benefit heart health but that the evidence is not overwhelming. It is a no-brainer that nutrition plays a pivotal role in health Continue reading →

Silk Road Medical announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at the VEITHsymposium in New York, USA (1923 November). In a headline presentation, Mahmoud Malas of the University of California, San Diego School of Medicine shared updated results for the ongoing TransCarotid Artery Revascularisation (TCAR) Surveillance Project contemporaneously comparing TCAR to the surgical standard of care, carotid endarterectomy (CEA). Our updated dataset now includes 6,526 matched patients Continue reading →

Treatment with evolocumab (Repatha; Amgen) within 1 year after a myocardial infarction (MI) was found to be beneficial in reducing the risk of subsequent MI, stroke, or cardiovascular death, according to new data from the FOURIER study. Findings were presented at the American Heart Association Scientific Sessions in Philadelphia, PA. In 2017, findings from the FOURIER trial led to the approval of evolocumab for the prevention of MI, stroke, and coronary revascularization in adults with established cardiovascular disease Continue reading →